Lifestyle-related diseases of the digestive system: A new in vitro model of hepatitis C virion production: Application of basic research on hepatitis C virus to clinical medicine

Journal of Pharmacological Sciences

Volumn 105, Issue 2, 2007, Pages 138-144

  Saito, Satoru ^a,b   Heller, Theo ^b   Yoneda, Masato ^a   Takahashi, Hirokazu ^a   Nakajima, Atsushi ^a   Liang, Jake T ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

HCV like particle; Hepatitis C virus (HCV); in vitro system; Life style related disease; Particle; Replication

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; COMPLEMENTARY DNA; GLYCOPROTEIN E1; INTERFERON; PROTEIN E2; RIBOZYME; UNCLASSIFIED DRUG; VIRUS PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; CLINICAL MEDICINE; DNA FLANKING REGION; DNA TRANSFECTION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEDICAL RESEARCH; MODEL; MOLECULAR CLONING; NONHUMAN; REPLICON; SHORT SURVEY; VIRION; VIRUS ASSEMBLY; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS LIKE AGENT; VIRUS PARTICLE; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS STRAIN;

EID: 36148961907     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FM0070040     Document Type: Short Survey

References (54)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-362.
2. Purcell R. The hepatitis C virus: overview. Hepatology. 1997;26:11S-14S.
3. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296-305.
4. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis. 2003;7:261-287.
5. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1990;87:6547-6549.
6. Tsukuma H, Hiyama S, Tanaka M, Nakao T, Yabuuchi T, Kitamura K, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. New Engl J Med. 1993;328:1797-1801.
7. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol. 2000;81:1631-1648.
8. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110-113.
9. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, et al. The origin of hepatitis C virus genotypes. J Gen Virol. 1997;78:321-328.
10. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000;13:223-235.
11. Manns MP, McHurchison JG, Gordon SC, Rustgi VK, Schiffman M, Reindollar R, et al. Pegintrferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
12. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006;41;17-27.
13. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science. 1997;277:570-574.
14. Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A. 1997;94:8738-8743.
15. Feray C, Gigou M, Samuel D, Ducot B, Maisonneuve P, Reynes M, et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med. 1998;128:810-816.
16. Choo QL, Kuo G. Ralston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A. 1994;94:1294-1298.
17. Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural protein assemble into viruslike particles in insect cells. J Virol. 1998;72:3827-3836.
18. Baumert TF, Wellnitz S, Aono S, Satoi J, Herion D, Tilman Gerlach J, et al. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Hepatology. 2000;32:610-617.
19. Blanchard E, Brand D, Trassard S, Goudeau A, Roingeard P. Hepatitis C virus-like particle morphogenesis. J Virol. 2002;76:4073-4079.
20. Ezelle HJ, Markovic D, Barber GN. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J Virol. 2002;76:12325-12334.
21. Clayton RF, Owsianka A, Aitken J, Graham S, Bhella D, Patel AH. Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol. 2002;76:7672-7682.
22. Triyatni M, Vergalla J, Davis AR, Hadlock KG, Foung SK, Liang TJ. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology. 2002;298;124-132.
23. Steinmann D, Barth H, Gissler B, Schurmann P, Adah MI, Gerlach JT, et al. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol. 2004;78:9030-9040.
24. Baumert TF, Vergalla J, Satoi J, Thomson M, Lechmann M, Herion D, et al. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology. 1999;117:1397-1407.
25. Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology. 2001;34:417-423.
26. Qiao M, Murata K, Davis AR, Jeong SH, Liang TJ. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology. 2003;37:52-59.
27. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science. 2000;290:1972-1974.
28. Pietschmann T, Lohmann V, Rutter G, Kurpanek K, Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol. 2001;75:1252-1264.
29. Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol. 2002;76:2997-3006.
30. Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol. 2001;75:8516-8623.
31. Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol. 2001;75:1437-1449.
32. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol. 2001;75:4614-4624.
33. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol. 2003;77:3181-3190.
34. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology. 2003;125:1808-1817.
35. Heller T, Saito S, Auerbach J, Williams T, Moreen TR, Jazwinski A, et al. An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A. 2005;102:2579-2583.
36. Cai Z, Liang TJ, Luo G. Effects of mutations of the initiation nucleotides on hepatitis C virus RNA replication in the cell. J Virol. 2004;78:3633-3643.
37. Kaito M, Watanabe S, Tsukiyama-Kohara K, Yamaguchi K, Kobayashi Y, Konishi M, et al. Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol. 1994;75:1755-1760.
38. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11:791-796.
39. Kato T, Furusaka A, Miyamoto M, Date T, Yasui K. Hiramoto J, et al. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol. 2001;64:334-339.
40. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A. 2006;103:3805-3809.
41. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science. 2005;309:623-626.
42. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A. 2006;103:2310-2315.
43. Kato T, Matsumura T, Heller T, Saito S, Sapp RK, Murthy K, et al. Production of infectious hepatitis C virus of various genotypes in cell cultures. J Virol. 2007;81:4405-4411.
44. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med. 2001;7:927-933.
45. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol. 2004;165:901-912.
46. Hiraga N, Imamura M, Tsuge M, Noguchi C, Takahashi S, Iwao E, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. FEBS Lett. 2007;581:1983-1987.
47. Triyatni M, Saunier B, Maruvada P, Davis AR, Ulianich L, Heller T, et al. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol. 2002;76:9335-9344.
48. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A. 2006;103:7408-7413.
49. McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol. 2006;44:411-421.
50. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007;132:1767-1777.
51. Kim SS, Peng LF, Lin W, Choe WH, Sakamoto N, Schreiber SL, et al. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology. 2007;132:311-320.
52. Fan X, Xu Y, Di Bisceglie AM. Efficient amplification and cloning of near full-length hepatitis C virus genome from clinical samples. Biochem Biophys Res Commun. 2006;346:1163-1172.
53. Zhou D, Fan X, Tan D, Xu Y, Tavis JE, Di Bisceglie AM. Separation of near full-length hepatitis C virus quasispecies variants from a complex population. J Virol Methods. 2007;141:220-224.
54. Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat. 2007;14:413-418.